Paratek expands commercial portfolio with Optinose

finance.yahoo.com/news/paratek-expands-commercial-portfolio-optinose-145719632.html

In This Article:
Paratek Pharmaceuticals has completed the acquisition of Optinose, valued at almost $330m, broadening its commercial product offerings.
The companies signed a definitive merger agreement in March 2025.
The portfolio of Paratek now includes its lead antibiotic, Nuzyra…

This story appeared on finance.yahoo.com, 2025-05-22 14:57:19.
The Entire Business World on a Single Page. Free to Use →